文献速递类风湿关节炎

类风湿关节炎低疾病活动度或缓解期停用与继续TNF抑制剂维持治疗的随机双盲安慰剂对照试验

Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial.
PubMed 文献 · Semin Arthritis Rheum · 2025-09-17

这项随机双盲安慰剂对照非劣效性试验纳入DAS28-CRP<2.6持续至少6个月的类风湿关节炎成人患者,按2:1随机分入停用TNF抑制剂(安慰剂)组或继续TNF抑制剂组。因中期分析拒绝非劣效性而提前终止,停药组复发率59.4%高于继续治疗组18.1%(HR 4.88;95%CI 2.05,11.61)。

要点

  • 停用TNF抑制剂组复发59.4%,继续治疗组18.1%,HR 4.88(95%CI 2.05,11.61)。
  • 停药组发作43.5%,继续治疗组15.1%。
  • 48周内停用阿达木单抗者成功停药55%,停用依那西普者26%。

核心结论

  • 停用TNF抑制剂维持治疗后的类风湿关节炎复发率高于继续治疗。

研究设计与样本

  • 随机、双盲、安慰剂对照非劣效性试验,纳入接受阿达木单抗、依那西普或英夫利西单抗治疗且DAS28-CRP<2.6持续至少6个月的类风湿关节炎成人患者。
  • 患者按2:1随机分入安慰剂注射/输注组(即停药)或继续活性TNF抑制剂组,患者、研究者和研究工作人员对治疗分配设盲。
  • 主要终点为48周内复发,定义为DAS28-CRP≥2.6或治疗升级;次要终点包括发作,定义为DAS28-CRP较基线升高≥1.2。
  • 研究基于中期分析拒绝非劣效性而提前终止,终止时共随机化102例患者(安慰剂组69例;活性TNF抑制剂组33例)。

主要发现

  • 复发发生于安慰剂组59.4%与活性TNF抑制剂组18.1%(HR 4.88;95%CI 2.05,11.61)。
  • 发作发生于安慰剂组43.5%与活性TNF抑制剂组15.1%。
  • 48周内,停用阿达木单抗的患者中55%成功停药,停用依那西普的患者中26%成功停药。

局限性

  • 研究基于中期分析拒绝非劣效性而提前终止,终止时共随机化102例患者(安慰剂组69例;活性TNF抑制剂组33例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with rheumatoid arthritis (RA) in sustained remission/low disease activity with tumor necrosis factor inhibitor (TNFi) treatment may be candidates for treatment de-escalation. We compared the frequency of relapses and flares of RA after TNFi discontinuation with TNFi continuation among such patients. We also investigated predictors of relapse. METHODS: This randomized, double-blind, placebo controlled noninferiority trial enrolled adults with RA who were treated with either adalimumab, etanercept, or infliximab, and who had a Disease Activity Score 28-C-reactive protein (DAS-CRP) < 2.6 for at least six months. Patients were randomly assigned 2:1 to either placebo injections/infusions (i.e. discontinuation) or active TNFi. Patients, investigators, and study staff were masked to treatment assignment. The primary endpoint was relapse over 48 weeks, defined as either DAS29-CRP ≥ 2.6 or treatment escalation. Secondary endpoints included flare, defined as an increase in DAS28-CRP ≥ 1.2 from baseline. RESULTS: The study was stopped early based on an interim analysis that rejected noninferiority. At study interruption, 102 patients (69 placebo; 33 active TNFi) were randomized. Relapses occurred in 59.4 % of the placebo group and 18.1 % of the active TNFi group (hazard ratio 4.88; 95 % confidence interval 2.05, 11.61). Flares occurred in 43.5 % and 15.1 % of these groups, respectively. Over 48 weeks, successful discontinuation was achieved in 55 % of patients who discontinued adalimumab and 26 % of patients who discontinued etanercept. CONCLUSION: Discontinuation of maintenance TNFi resulted in higher rates of relapse of RA than continuation. TRIAL REGISTRATION: Clinicaltrials.gov NCT01793519.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ward MM, Weinstein A, Alejandro-Silva P, et al. Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial. Semin Arthritis Rheum. 2025. PMID: 41045868. doi:10.1016/j.semarthrit.2025.152831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。